<DOC>
	<DOCNO>NCT00689624</DOCNO>
	<brief_summary>This study evaluate efficacy FOLOFOXIRI plus Cetuximab combination young patient good performance status unresectable metastatic colorectal cancer .</brief_summary>
	<brief_title>Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer</brief_title>
	<detailed_description>The combination FOLFOXIRI plus cetuximab reasonable safe regimen especially patient good performance status . The estimated benefit combination great possible risk , especially patient become resectable treatment . It extremely interesting evaluate resectability rate specific group patient good performance status unresectable disease treat active chemotherapeutic agent cetuximab</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Patients histologically proven metastatic adenocarcinoma colon rectum Previous chemotherapy metastatic disease allow . Patients receive prior adjuvant 5FUbased chemotherapy eligible remain free disease least 6 month completion adjuvant therapy Patients operable metastatic disease exclude study Age 1870 year Performance status ( ECOG ) 01 At least one bidimensionally measurable lesion &gt; = 2cm Life expectancy least 6 month Adequate hematologic parameter ( absolute neutrophil count &gt; = 1.5x109/L platelet &gt; =100x109/L ) Creatinine total bilirubin &lt; 1.25 time upper limit normal Aspartate alanine aminotransferase &lt; 3.0 time upper limit normal ( &lt; 5 time case liver mets ) Absence active infection malnutrition ( loss 20 % body weight ) No history second primary tumor nonmelanoma skin cancer situ cervical carcinoma . curatively treated Patients treat palliative radiotherapy measurable metastatic disease outside irradiation field . Patients severe cardiac dysfunction , liver metastasis involve 50 % liver parenchyma , chronic diarrhea , prior irradiation affect 30 % active bone marrow exclude . All patient sign write informed consent order participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>FOLFOXIRI</keyword>
</DOC>